Simone Dal Corso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simone Dal Corso has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Rodrigo Abensur Athanazio
Pulmonary Department, Heart Institute (InCor), School of Medicine, University of São Paulo, São Paulo 04023-062, Brazil
7 shared publications - Samia Zahi Rached
Pneumology Department, Heart Institute, University of São Paulo, São Paulo, Brazil
7 shared publications - Dirceu Solé
Universidade Federal de São Paulo, Brazil
5 shared publications - Fernanda Cordoba Lanza
Universidade Federal de Minas Gerais
5 shared publications - Anderson Alves de Camargo
Postgraduate Program in Rehabilitation Sciences, Universidade Nove de Julho, São Paulo, Brazil
4 shared publications - Gustavo Falbo Wandalsen
Universidade Federal de São Paulo, Brazil
4 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 83
Effects of resistance training with/without Photobiomodulation on muscle and respiratory function in difficult-to-control asthma: a randomized trial
Difficult-to-Control Asthma (DTCA) is characterized by persistent symptoms, frequent exacerbations, and reduced functional capacity despite optimized pharmacological therapy. Patients with DTCA commonly exhibit peripheral muscle dysfunction, making strategies that may potentiate the effects of resistance training clinically relevant. Photobiomodulation therapy (PBMT) has been investigated as a modality capable of improving muscle performance and exercise tolerance. The aim of this study was to determine whether combining resistance training with LED-based PBMT (RT+LEDT) results in greater improvements in peripheral muscle strength and functional exercise capacity compared with resistance training alone in adults with DTCA. This randomized, triple-blind controlled trial included 30 adults with DTCA who met predefined inclusion and exclusion criteria. Participants were allocated equally to an experimental group (RT+LEDT; n = 15) or a control group (RT; n = 15). Both groups completed supervised resistance training twice weekly for 12 weeks. The experimental group received active PBMT before each session, while the control group received placebo PBMT. The primary outcome was peripheral muscle strength assessed by one-repetition maximum (1RM). Secondary outcomes included cardiopulmonary exercise test variables, shuttle walk test performance, spirometry, physical activity level, and asthma control. Post-intervention group comparisons were performed using independent t-tests. Compared with RT alone, RT+LEDT produced greater post-treatment gains in 1RM strength across major muscle groups, along with significant improvements in oxygen consumption at the anaerobic threshold and shuttle walk test distance. No between-group differences were observed in pulmonary function or asthma control. PBMT combined with resistance training yielded clinically meaningful improvements in muscle strength and functional capacity, suggesting its potential as an adjunctive strategy in rehabilitation programs for DTCA.
- 30 April 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 83
Open AccessEffects of resistance training with/without Photobiomodulation on muscle and respiratory function in difficult-to-control asthma: a randomized trial
Difficult-to-Control Asthma (DTCA) is characterized by persistent symptoms, frequent exacerbations, and reduced functional capacity despite optimized pharmacological therapy. Patients with DTCA commonly exhibit peripheral muscle dysfunction, making strategies that may potentiate the effects of resistance training clinically relevant. Photobiomodulation therapy (PBMT) has been investigated as a modality capable of improving muscle performance and exercise tolerance. The aim of this study was to determine whether combining resistance training with LED-based PBMT (RT+LEDT) results in greater improvements in peripheral muscle strength and functional exercise capacity compared with resistance training alone in adults with DTCA. This randomized, triple-blind controlled trial included 30 adults with DTCA who met predefined inclusion and exclusion criteria. Participants were allocated equally to an experimental group (RT+LEDT; n = 15) or a control group (RT; n = 15). Both groups completed supervised resistance training twice weekly for 12 weeks. The experimental group received active PBMT before each session, while the control group received placebo PBMT. The primary outcome was peripheral muscle strength assessed by one-repetition maximum (1RM). Secondary outcomes included cardiopulmonary exercise test variables, shuttle walk test performance, spirometry, physical activity level, and asthma control. Post-intervention group comparisons were performed using independent t-tests. Compared with RT alone, RT+LEDT produced greater post-treatment gains in 1RM strength across major muscle groups, along with significant improvements in oxygen consumption at the anaerobic threshold and shuttle walk test distance. No between-group differences were observed in pulmonary function or asthma control. PBMT combined with resistance training yielded clinically meaningful improvements in muscle strength and functional capacity, suggesting its potential as an adjunctive strategy in rehabilitation programs for DTCA.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 44
Exercise training program in children and adolescents with asthma: a randomized clinical trial
Objective: To evaluate, in children and adolescents with asthma, the effects of an 8-week exercise training program on exercise capacity. Methods: Single-blind, randomized clinical trial in participants with asthma between six and 17 years old under regular treatment. The intervention group performed supervised aerobic and resistance training, and the control group performed supervised stretching in 60-minute sessions twice a week for eight weeks. They were assessed at baseline and following the intervention. The primary outcomes were (VO2peak) and distance walked on the Modified Shuttle Test (MST). Secondary outcomes included quality of life, physical activity in daily living, and serum inflammatory profile. The analyses were intention-to-treat and per protocol. Results: Thirty participants in the intervention group and 29 in the control group, mean age 10±3 years old, normal lung function (forced expiratory volume — FEV1/forced vital capacity — FVC: 86±8), Global Initiative for Asthma (GINA) step: 2 (1–3). No significant differences between groups were observed at the end of the protocol regarding all outcomes. The VO2 peak was 40.3±12.4 mL/kg in the intervention group and 39.2±16.0 mL/kg in the control group (p=0.764). The distance walked on the MST was 852±219 m for the intervention group and 759±255 m for the control group (p=0.142). Conclusions: A twice-weekly, 8-week exercise program for children and adolescents with asthma did not improve exercise capacity, quality of life, or the inflammatory profile. The optimal frequency of intervention for this population requires further investigation.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 44
Open AccessExercise training program in children and adolescents with asthma: a randomized clinical trial
Objective: To evaluate, in children and adolescents with asthma, the effects of an 8-week exercise training program on exercise capacity. Methods: Single-blind, randomized clinical trial in participants with asthma between six and 17 years old under regular treatment. The intervention group performed supervised aerobic and resistance training, and the control group performed supervised stretching in 60-minute sessions twice a week for eight weeks. They were assessed at baseline and following the intervention. The primary outcomes were (VO2peak) and distance walked on the Modified Shuttle Test (MST). Secondary outcomes included quality of life, physical activity in daily living, and serum inflammatory profile. The analyses were intention-to-treat and per protocol. Results: Thirty participants in the intervention group and 29 in the control group, mean age 10±3 years old, normal lung function (forced expiratory volume — FEV1/forced vital capacity — FVC: 86±8), Global Initiative for Asthma (GINA) step: 2 (1–3). No significant differences between groups were observed at the end of the protocol regarding all outcomes. The VO2 peak was 40.3±12.4 mL/kg in the intervention group and 39.2±16.0 mL/kg in the control group (p=0.764). The distance walked on the MST was 852±219 m for the intervention group and 759±255 m for the control group (p=0.142). Conclusions: A twice-weekly, 8-week exercise program for children and adolescents with asthma did not improve exercise capacity, quality of life, or the inflammatory profile. The optimal frequency of intervention for this population requires further investigation.
- Open Access
- 1 January 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 149-158
Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD
Purpose: Oral corticosteroids (OCS) are recommended for the treatment of exacerbations in people with COPD; however, high cumulative lifetime doses (≥ 1000mg prednisolone-equivalent) are associated with adverse health effects. This issue is well defined in asthma but is less well understood in COPD. The aim of this study was to examine cumulative OCS dispensed to people with COPD over 12 months. Patients and Methods: This was a secondary analysis of data from two randomised controlled trials involving people with COPD followed up for 12 months following pulmonary rehabilitation. Clinical and administrative (respiratory-related hospital admissions and emergency presentations, dispensed OCS and COPD maintenance medications) data were examined to determine cumulative OCS dose relative to the 1000mg threshold and the relationship with clinical features. Results: Of 232 participants (126 females, age mean 68 ± SD 9 years, FEV1 53 ± 22% predicted), 48% (n = 112) were dispensed OCS at least once over 12 months. Sixty-two participants (26%) were dispensed ≥ 1000mg. Participants with a high cumulative dose were more likely to have had a respiratory admission (OR 4.1, 95% CI 2.3 to 8.7) and greater breathlessness (modified Medical Research Council scale ≥ 2, OR 2.5, 95% CI 1.3 to 5.0); no relationship with disease severity or maintenance medications was demonstrated. Conclusion: One in four people with COPD were dispensed unsafe lifetime cumulative OCS doses over a period of only 12 months. Further work is needed to determine the magnitude of this issue in COPD and strategies to address exposure to high doses of OCS.
- 1 January 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 149-158
Open AccessCumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD
Purpose: Oral corticosteroids (OCS) are recommended for the treatment of exacerbations in people with COPD; however, high cumulative lifetime doses (≥ 1000mg prednisolone-equivalent) are associated with adverse health effects. This issue is well defined in asthma but is less well understood in COPD. The aim of this study was to examine cumulative OCS dispensed to people with COPD over 12 months. Patients and Methods: This was a secondary analysis of data from two randomised controlled trials involving people with COPD followed up for 12 months following pulmonary rehabilitation. Clinical and administrative (respiratory-related hospital admissions and emergency presentations, dispensed OCS and COPD maintenance medications) data were examined to determine cumulative OCS dose relative to the 1000mg threshold and the relationship with clinical features. Results: Of 232 participants (126 females, age mean 68 ± SD 9 years, FEV1 53 ± 22% predicted), 48% (n = 112) were dispensed OCS at least once over 12 months. Sixty-two participants (26%) were dispensed ≥ 1000mg. Participants with a high cumulative dose were more likely to have had a respiratory admission (OR 4.1, 95% CI 2.3 to 8.7) and greater breathlessness (modified Medical Research Council scale ≥ 2, OR 2.5, 95% CI 1.3 to 5.0); no relationship with disease severity or maintenance medications was demonstrated. Conclusion: One in four people with COPD were dispensed unsafe lifetime cumulative OCS doses over a period of only 12 months. Further work is needed to determine the magnitude of this issue in COPD and strategies to address exposure to high doses of OCS.
- Open Access
- 9 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e68582
Effect of dual bronchodilation on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis: A randomized controlled double-blind cross-over study protocol (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Bronchodilators (BDs) have been used therapeutically to improve exercise capacity in patients with other chronic respiratory diseases. However, the effect of BDs on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis (NCFB) is poorly understood. Objective: To evaluate the effects of BDs on exercise capacity and thoracoabdominal kinematics in patients with NCFB. Methods: This cross-over randomized controlled trial will involve 45 outpatients with NCFB aged 18 to 59 years. They will be evaluated in three visits. On Day 1, the maximal exercise capacity (cardiopulmonary exercise test; Wpeak) will be assessed. On Day 2, individuals will be randomized to receive either BDs (ipratropium bromide 160 µg and fenoterol hydrobromide 400 µg) or a placebo and then undergo simultaneous endurance exercise capacity (constant work-rate exercise test) and thoracoabdominal kinematics (TK) (optoelectronic plethysmography) assessments. After at least one-week washout (Day 3), the individuals will repeat the same assessments as on Day 2, in reverse order. The time to the limit of tolerance (Tlim) will be obtained in both groups (the BD and placebo groups) as the primary outcome. TK will be assessed at three-time points: at rest, during unloaded exercise, and at 75%Wpeak. The total chest wall and compartmental volumes, as well as thoracoabdominal asynchrony, will be assessed. The assessors and patients will be blinded to the interventions (BDs or placebo). Data will be compared using t-tests or Wilcoxon and repeated-measures ANOVA or Friedman tests. Categorical data will be analysed using the chi-square test or Fisher's test. The associations among variables will be analysed using Pearson or Spearman correlation. The significance level will be set at 5% (P<.05). Results: The ethics approval was granted in November 2018, and a pilot study was commenced in April 2019 but was interrupted due to the COVID-19 pandemic. The study restarted in April 2022, and data collection is ongoing, which is anticipated to continue until July 2025. Publication of results is anticipated from 2025 to 2026. Conclusions: There is no evidence that bronchodilators can improve NCFB patients' exercise capacity. This trial will compare the endurance exercise capacity of the same individual with and without dual bronchodilation. If successful, this study will demonstrate that exercise capacity can be improved with the use of bronchodilators in adults with NCFB. Clinical Trial: ClinicalTrials.gov NCT05183841; https://clinicaltrials.gov/study/NCT05183841
- 9 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e68582
Open AccessEffect of dual bronchodilation on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis: A randomized controlled double-blind cross-over study protocol (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Bronchodilators (BDs) have been used therapeutically to improve exercise capacity in patients with other chronic respiratory diseases. However, the effect of BDs on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis (NCFB) is poorly understood. Objective: To evaluate the effects of BDs on exercise capacity and thoracoabdominal kinematics in patients with NCFB. Methods: This cross-over randomized controlled trial will involve 45 outpatients with NCFB aged 18 to 59 years. They will be evaluated in three visits. On Day 1, the maximal exercise capacity (cardiopulmonary exercise test; Wpeak) will be assessed. On Day 2, individuals will be randomized to receive either BDs (ipratropium bromide 160 µg and fenoterol hydrobromide 400 µg) or a placebo and then undergo simultaneous endurance exercise capacity (constant work-rate exercise test) and thoracoabdominal kinematics (TK) (optoelectronic plethysmography) assessments. After at least one-week washout (Day 3), the individuals will repeat the same assessments as on Day 2, in reverse order. The time to the limit of tolerance (Tlim) will be obtained in both groups (the BD and placebo groups) as the primary outcome. TK will be assessed at three-time points: at rest, during unloaded exercise, and at 75%Wpeak. The total chest wall and compartmental volumes, as well as thoracoabdominal asynchrony, will be assessed. The assessors and patients will be blinded to the interventions (BDs or placebo). Data will be compared using t-tests or Wilcoxon and repeated-measures ANOVA or Friedman tests. Categorical data will be analysed using the chi-square test or Fisher's test. The associations among variables will be analysed using Pearson or Spearman correlation. The significance level will be set at 5% (P<.05). Results: The ethics approval was granted in November 2018, and a pilot study was commenced in April 2019 but was interrupted due to the COVID-19 pandemic. The study restarted in April 2022, and data collection is ongoing, which is anticipated to continue until July 2025. Publication of results is anticipated from 2025 to 2026. Conclusions: There is no evidence that bronchodilators can improve NCFB patients' exercise capacity. This trial will compare the endurance exercise capacity of the same individual with and without dual bronchodilation. If successful, this study will demonstrate that exercise capacity can be improved with the use of bronchodilators in adults with NCFB. Clinical Trial: ClinicalTrials.gov NCT05183841; https://clinicaltrials.gov/study/NCT05183841
- Open Access
- 9 November 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Effect of dual bronchodilation on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis: A randomized controlled double-blind crossover study protocol (Preprint)
BACKGROUND Bronchodilators (BDs) have been used therapeutically to improve exercise capacity in patients with other chronic respiratory diseases. However, the effect of BDs on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis (NCFB) is poorly understood. OBJECTIVE To evaluate the effects of BDs on exercise capacity and thoracoabdominal kinematics in patients with NCFB. METHODS This crossover randomized controlled trial will involve 45 outpatients with NCFB aged 18 to 59 years. They will be evaluated in three visits. On Day 1, the maximal exercise capacity (cardiopulmonary exercise test) (Wpeak) will be assessed. On Day 2, individuals will be randomized to receive either BDs (ipratropium bromide 160 µg and fenoterol hydrobromide 400 µg) or a placebo and then undergo simultaneous endurance exercise capacity (constant work-rate exercise test) and thoracoabdominal kinematics (TK) (optoelectronic plethysmography) assessments. After a one-week washout (Day 3), the individuals will repeat the same assessments as on Day 2, in reverse order. The time to the limit of tolerance (Tlim) will be obtained in both groups (the BD and placebo groups) as the primary outcome. TK will be assessed at three time points: at rest, during unloaded exercise, and at 75%Wpeak. The total chest wall and compartmental volumes, as well as thoracoabdominal asynchrony, will be assessed. The assessors and patients will be blinded to the interventions (BDs or placebo). Data will be compared using t tests or Wilcoxon tests and repeated-measures ANOVA or Friedman tests. Categorical data will be analysed using the chi-square test or Fisher’s test. The associations among variables will be analysed using Pearson or Spearman correlation. The significance level will be set at 5% (P<.05). RESULTS This is a study protocol and the research is ongoing. CONCLUSIONS If successful, this study will demonstrate that the use of bronchodilators can improve exercise capacity and reduce thoracoabdominal asynchrony in adults with NCFB. CLINICALTRIAL Clinical Trials.gov PRS (Protocol Registration and Results System): NCT05183841.
- 9 November 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffect of dual bronchodilation on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis: A randomized controlled double-blind crossover study protocol (Preprint)
BACKGROUND Bronchodilators (BDs) have been used therapeutically to improve exercise capacity in patients with other chronic respiratory diseases. However, the effect of BDs on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis (NCFB) is poorly understood. OBJECTIVE To evaluate the effects of BDs on exercise capacity and thoracoabdominal kinematics in patients with NCFB. METHODS This crossover randomized controlled trial will involve 45 outpatients with NCFB aged 18 to 59 years. They will be evaluated in three visits. On Day 1, the maximal exercise capacity (cardiopulmonary exercise test) (Wpeak) will be assessed. On Day 2, individuals will be randomized to receive either BDs (ipratropium bromide 160 µg and fenoterol hydrobromide 400 µg) or a placebo and then undergo simultaneous endurance exercise capacity (constant work-rate exercise test) and thoracoabdominal kinematics (TK) (optoelectronic plethysmography) assessments. After a one-week washout (Day 3), the individuals will repeat the same assessments as on Day 2, in reverse order. The time to the limit of tolerance (Tlim) will be obtained in both groups (the BD and placebo groups) as the primary outcome. TK will be assessed at three time points: at rest, during unloaded exercise, and at 75%Wpeak. The total chest wall and compartmental volumes, as well as thoracoabdominal asynchrony, will be assessed. The assessors and patients will be blinded to the interventions (BDs or placebo). Data will be compared using t tests or Wilcoxon tests and repeated-measures ANOVA or Friedman tests. Categorical data will be analysed using the chi-square test or Fisher’s test. The associations among variables will be analysed using Pearson or Spearman correlation. The significance level will be set at 5% (P<.05). RESULTS This is a study protocol and the research is ongoing. CONCLUSIONS If successful, this study will demonstrate that the use of bronchodilators can improve exercise capacity and reduce thoracoabdominal asynchrony in adults with NCFB. CLINICALTRIAL Clinical Trials.gov PRS (Protocol Registration and Results System): NCT05183841.
- 21 June 2024
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 47 (5) , 1314-1323
The Bed Bridge Test: a new functional test for hospital inpatients – a feasibility and measurement study
To develop and assess the Bed Bridge Test's (BBT) feasibility, safety, and clinimetric properties and evaluate functional capacity in hospitalised patients. This feasibility and measurement study examined four BBT versions, including the timed-limited at 30 and 60 s and repetition-limited at 5 and 10 times, in hospitalised patients in a university hospital in Brazil. Ninety-two functionally stable patients with respiratory, gastrointestinal, or post-surgical conditions participated. Participants completed the BBT versions in a random order. BBT concurrent criterion validity was evaluated using the Short Physical Performance Battery (SPPB), Sit-to-Stand (STS) test, and Functional Status Score (FSS). The participants were 51 ± 17 years old, 60% female, and 66% with clinical conditions. All participants completed the BBT versions without adverse events. Test-retest reliability was good-excellent (intraclass correlation coefficient >0.87) for all BBT versions, with acceptable agreement parameters and minimal detectable changes. The time-limited versions of the BBT might be affected by a ceiling effect. Floor effects were minimal for all BBT versions. BBT showed moderate associations with SPPB and STS and weak associations with FSS. The BBT is feasible and has promising measurement properties.
- 21 June 2024
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 47 (5) , 1314-1323
The Bed Bridge Test: a new functional test for hospital inpatients – a feasibility and measurement study
To develop and assess the Bed Bridge Test's (BBT) feasibility, safety, and clinimetric properties and evaluate functional capacity in hospitalised patients. This feasibility and measurement study examined four BBT versions, including the timed-limited at 30 and 60 s and repetition-limited at 5 and 10 times, in hospitalised patients in a university hospital in Brazil. Ninety-two functionally stable patients with respiratory, gastrointestinal, or post-surgical conditions participated. Participants completed the BBT versions in a random order. BBT concurrent criterion validity was evaluated using the Short Physical Performance Battery (SPPB), Sit-to-Stand (STS) test, and Functional Status Score (FSS). The participants were 51 ± 17 years old, 60% female, and 66% with clinical conditions. All participants completed the BBT versions without adverse events. Test-retest reliability was good-excellent (intraclass correlation coefficient >0.87) for all BBT versions, with acceptable agreement parameters and minimal detectable changes. The time-limited versions of the BBT might be affected by a ceiling effect. Floor effects were minimal for all BBT versions. BBT showed moderate associations with SPPB and STS and weak associations with FSS. The BBT is feasible and has promising measurement properties.
- Open Access
- 28 May 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (5) , 1538-1546
Comparison of the effectiveness of the helmet interface using flow meters versus the mechanical ventilator for non-invasive ventilation in patients with coronavirus disease 2019. Controlled and randomized clinical trial
Introduction: This study aimed to compare the effectiveness of two methods for non-invasive mechanical ventilation in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using a helmet interface with a flow meter and positive end-expiratory pressure valve versus a traditional mechanical ventilator.Material and methods: We conducted a single-center randomized clinical trial involving 100 adult SARS-CoV-2 patients in a specialized private hospital. Participants were randomly assigned to two groups: one using the helmet interface with a flow meter and positive end-expiratory pressure valve and the other employing conventional mechanical ventilation. Our study included participant selection, blood gas analysis, assessment of respiratory rate, peripheral oxygen saturation, modified Borg scale scores, and a visual analog scale.Results: The study showed no significant difference in intubation rates between the mechanical ventilation (54.3%) and helmet interface with flow meter and positive end-expiratory pressure valve (46.8%) groups (p = 0.37). Additionally, the helmet group had a shorter average duration of use (3.4 ±1.6 days) compared to the mechanical ventilation group (4.0 ±1.9 days). The helmet group also had a shorter average hospitalization duration (15.9 ±7.9 days) compared to the mechanical ventilation group (17.1 ±9.5 days).Conclusions: This single-center randomized clinical trial found no statistically significant differences between the two methods of non-invasive ventilation. Implications for clinical practice: using the helmet interface with the flow meter and positive end-expiratory pressure valve can simplify device installation, potentially reducing the need for intubation, making it a valuable tool for nurses and physiotherapists in daily clinical practice.
- 28 May 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (5) , 1538-1546
Open AccessComparison of the effectiveness of the helmet interface using flow meters versus the mechanical ventilator for non-invasive ventilation in patients with coronavirus disease 2019. Controlled and randomized clinical trial
Introduction: This study aimed to compare the effectiveness of two methods for non-invasive mechanical ventilation in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using a helmet interface with a flow meter and positive end-expiratory pressure valve versus a traditional mechanical ventilator.Material and methods: We conducted a single-center randomized clinical trial involving 100 adult SARS-CoV-2 patients in a specialized private hospital. Participants were randomly assigned to two groups: one using the helmet interface with a flow meter and positive end-expiratory pressure valve and the other employing conventional mechanical ventilation. Our study included participant selection, blood gas analysis, assessment of respiratory rate, peripheral oxygen saturation, modified Borg scale scores, and a visual analog scale.Results: The study showed no significant difference in intubation rates between the mechanical ventilation (54.3%) and helmet interface with flow meter and positive end-expiratory pressure valve (46.8%) groups (p = 0.37). Additionally, the helmet group had a shorter average duration of use (3.4 ±1.6 days) compared to the mechanical ventilation group (4.0 ±1.9 days). The helmet group also had a shorter average hospitalization duration (15.9 ±7.9 days) compared to the mechanical ventilation group (17.1 ±9.5 days).Conclusions: This single-center randomized clinical trial found no statistically significant differences between the two methods of non-invasive ventilation. Implications for clinical practice: using the helmet interface with the flow meter and positive end-expiratory pressure valve can simplify device installation, potentially reducing the need for intubation, making it a valuable tool for nurses and physiotherapists in daily clinical practice.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 21
Fidelity of a home-based pulmonary rehabilitation program in people with COPD referred from primary care
Purpose: Pulmonary rehabilitation (PR) is highly effective but underutilised. Pathways to home-based PR (HBPR) from general practice could improve utilisation, but program fidelity in this setting is unknown. This study aimed to explore the fidelity of HBPR in people referred from general practice. Methods: Secondary analysis of intervention-group data from two-arm cluster RCT (RADICALS-interdisciplinary intervention for people with COPD including smoking cessation support, home medicine reviews and 8-weeks HBPR). HBPR fidelity assessed by the extent to which exercise training was prescribed according to protocol. Completion of HBPR and contributing factors were determined. Results: 107 participants (68% of intervention group) were referred to HBPR, with n = 75 (70%) commencing the program (mean age 68 years, FEV1 65% predicted, median mMRC 1). Aerobic training was prescribed according to protocol for 74% of participants in week one, and on average 89% of participants in weeks 2–8. Resistance training was prescribed according to protocol for 98% and 88% of participants (Week 1 and Weeks 2–8, respectively). Rehabilitation completers ( n = 57, 76%) were 26 times more likely to have attended the Week 2 phone call (95% CI 2–352). Clinically meaningful improvements were achieved in health-related quality of life (SGRQ) and health status (CAT) following rehabilitation. Conclusion: PR program fidelity can be maintained when delivering HBPR to people with COPD referred directly from general practice. Early engagement with PR may be key to supporting rehabilitation completion.
- 1 January 2024
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 21
Open AccessFidelity of a home-based pulmonary rehabilitation program in people with COPD referred from primary care
Purpose: Pulmonary rehabilitation (PR) is highly effective but underutilised. Pathways to home-based PR (HBPR) from general practice could improve utilisation, but program fidelity in this setting is unknown. This study aimed to explore the fidelity of HBPR in people referred from general practice. Methods: Secondary analysis of intervention-group data from two-arm cluster RCT (RADICALS-interdisciplinary intervention for people with COPD including smoking cessation support, home medicine reviews and 8-weeks HBPR). HBPR fidelity assessed by the extent to which exercise training was prescribed according to protocol. Completion of HBPR and contributing factors were determined. Results: 107 participants (68% of intervention group) were referred to HBPR, with n = 75 (70%) commencing the program (mean age 68 years, FEV1 65% predicted, median mMRC 1). Aerobic training was prescribed according to protocol for 74% of participants in week one, and on average 89% of participants in weeks 2–8. Resistance training was prescribed according to protocol for 98% and 88% of participants (Week 1 and Weeks 2–8, respectively). Rehabilitation completers ( n = 57, 76%) were 26 times more likely to have attended the Week 2 phone call (95% CI 2–352). Clinically meaningful improvements were achieved in health-related quality of life (SGRQ) and health status (CAT) following rehabilitation. Conclusion: PR program fidelity can be maintained when delivering HBPR to people with COPD referred directly from general practice. Early engagement with PR may be key to supporting rehabilitation completion.
- Open Access
- 21 December 2023
- Published by Wiley in Medical Journal of Australia
- Vol. 220 (2) , 91-96
The Alfred Health post‐COVID‐19 service, Melbourne, 2020–2022: an observational cohort study
Objectives: To determine the uptake of the Alfred Health Post‐COVID service among people hospitalised with coronavirus disease 2019 (COVID‐19) or referred by general practitioners; to describe their characteristics and symptoms at eight weeks and the clinical services they required.Study design: Observational cohort study.Setting: Outpatient post‐COVID‐19 follow‐up service in a tertiary Melbourne hospital.Participants: All people admitted to Alfred Health (inpatients, hospital‐in‐the‐home) with COVID‐19, 19 March 2020 – 28 December 2022; people with persistent symptoms referred by general practitioners in the Alfred Health catchment area during 2022.Intervention: Questionnaire‐based symptom assessment eight weeks after onset of COVID‐19. Dyspnoea, fatigue, depression, anxiety, and post‐traumatic stress disorder were assessed with standardised tools, as were health status and health‐related quality of life; return to work or study, weight loss, and altered cognition and memory were also assessed. Screening was followed by physical assessment and management at the service (specialist general medicine review, physiotherapist, allied health assistant, neuropsychologist) and referral to other specialist medical services as required.Main outcome measures: Proportion of eligible people who used the service for follow‐up at eight weeks; proportions of service users who reported symptoms and return to pre‐COVID‐19 employment or study; clinical services required by service users.Results: Of 6712 people invited for screening, 726 completed questionnaires (11%). At least one persistent symptom was reported by 385 of 642 respondents (60% of respondents, 5.7% of invitees), most frequently memory (371 of 656, 57%) or concentration problems (431 of 656, 66%), dyspnoea (197 of 703, 28%), and extreme fatigue (189 of 673, 28%). Sixty‐seven of 453 respondents had not returned to pre‐COVID‐19 work or study (15%). People were referred to a variety of medical and non‐medical services for management, including specialist medical clinics, allied health, and rehabilitation. Among 71 people who also completed questionnaires at twelve months, the proportions who reported fatigue, anxiety, and memory and concentration changes were similar at both assessments.Conclusions: After acute COVID‐19 that required hospital admission or was followed by persistent symptoms in community care, a small proportion of people (5.7%) reported symptoms that required medical and allied health specialist assessment and management. Our findings may assist planning services for people with long COVID.
- 21 December 2023
- Published by Wiley in Medical Journal of Australia
- Vol. 220 (2) , 91-96
Open AccessThe Alfred Health post‐COVID‐19 service, Melbourne, 2020–2022: an observational cohort study
Objectives: To determine the uptake of the Alfred Health Post‐COVID service among people hospitalised with coronavirus disease 2019 (COVID‐19) or referred by general practitioners; to describe their characteristics and symptoms at eight weeks and the clinical services they required.Study design: Observational cohort study.Setting: Outpatient post‐COVID‐19 follow‐up service in a tertiary Melbourne hospital.Participants: All people admitted to Alfred Health (inpatients, hospital‐in‐the‐home) with COVID‐19, 19 March 2020 – 28 December 2022; people with persistent symptoms referred by general practitioners in the Alfred Health catchment area during 2022.Intervention: Questionnaire‐based symptom assessment eight weeks after onset of COVID‐19. Dyspnoea, fatigue, depression, anxiety, and post‐traumatic stress disorder were assessed with standardised tools, as were health status and health‐related quality of life; return to work or study, weight loss, and altered cognition and memory were also assessed. Screening was followed by physical assessment and management at the service (specialist general medicine review, physiotherapist, allied health assistant, neuropsychologist) and referral to other specialist medical services as required.Main outcome measures: Proportion of eligible people who used the service for follow‐up at eight weeks; proportions of service users who reported symptoms and return to pre‐COVID‐19 employment or study; clinical services required by service users.Results: Of 6712 people invited for screening, 726 completed questionnaires (11%). At least one persistent symptom was reported by 385 of 642 respondents (60% of respondents, 5.7% of invitees), most frequently memory (371 of 656, 57%) or concentration problems (431 of 656, 66%), dyspnoea (197 of 703, 28%), and extreme fatigue (189 of 673, 28%). Sixty‐seven of 453 respondents had not returned to pre‐COVID‐19 work or study (15%). People were referred to a variety of medical and non‐medical services for management, including specialist medical clinics, allied health, and rehabilitation. Among 71 people who also completed questionnaires at twelve months, the proportions who reported fatigue, anxiety, and memory and concentration changes were similar at both assessments.Conclusions: After acute COVID‐19 that required hospital admission or was followed by persistent symptoms in community care, a small proportion of people (5.7%) reported symptoms that required medical and allied health specialist assessment and management. Our findings may assist planning services for people with long COVID.